Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial (Q43833266)

27 November 2017

Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial (English)

1 reference

27 November 2017

1 reference

James D Otvos

1

1 reference

27 November 2017

Irina Shalaurova

series ordinal

2

1 reference

27 November 2017

David S Freedman

series ordinal

3

1 reference

27 November 2017

Robert S Rosenson

series ordinal

4

1 reference

27 November 2017

1 January 2002

1 reference

27 November 2017

1 reference

27 November 2017

160

1 reference

27 November 2017

41-48

1 reference

27 November 2017

1

1 reference

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Did grandma give you heart disease? The new battle against coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Effect of fluvastatin on low-density lipoprotein peak particle diameter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900544-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(01)00544-5

1 reference

27 November 2017

1 reference